{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T17:21:48Z","timestamp":1778001708737,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s40264-022-01260-6","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T19:03:17Z","timestamp":1671044597000},"page":"195-208","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Mortality in Patients with Parkinson\u2019s Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0994-5820","authenticated-orcid":false,"given":"J. Bradley","family":"Layton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1066-0358","authenticated-orcid":false,"given":"Joan","family":"Forns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8842-9431","authenticated-orcid":false,"given":"Lisa J.","family":"McQuay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3014-7508","authenticated-orcid":false,"given":"Heather E.","family":"Danysh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen","family":"Dempsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5760-6965","authenticated-orcid":false,"given":"Mary S.","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Ellen","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"issue":"11","key":"1260_CR1","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1080\/17512433.2017.1369405","volume":"10","author":"Y Kianirad","year":"2017","unstructured":"Kianirad Y, Simuni T. Pimavanserin, a novel antipsychotic for management of Parkinson\u2019s disease psychosis. Expert Rev Clin Pharmacol. 2017;10(11):1161\u20138. https:\/\/doi.org\/10.1080\/17512433.2017.1369405.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"8","key":"1260_CR2","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/archneurol.2010.166","volume":"67","author":"EB Forsaa","year":"2010","unstructured":"Forsaa EB, Larsen JP, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67(8):996\u20131001. https:\/\/doi.org\/10.1001\/archneurol.2010.166.","journal-title":"Arch Neurol"},{"issue":"3","key":"1260_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248968","volume":"16","author":"S Mantri","year":"2021","unstructured":"Mantri S, Klawson E, Albert S, Rapoport R, Precht C, Glancey S, et al. The experience of care partners of patients with Parkinson\u2019s disease psychosis. PLoS ONE. 2021;16(3): e0248968. https:\/\/doi.org\/10.1371\/journal.pone.0248968.","journal-title":"PLoS ONE"},{"issue":"1","key":"1260_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246121","volume":"16","author":"J Forns","year":"2021","unstructured":"Forns J, Layton JB, Bartsch J, Turner ME, Dempsey C, Anthony M, et al. Increased risk of falls and fractures in patients with psychosis and Parkinson disease. PLoS ONE. 2021;16(1): e0246121. https:\/\/doi.org\/10.1371\/journal.pone.0246121.","journal-title":"PLoS ONE"},{"issue":"1","key":"1260_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/practneurol-2018-002075","volume":"20","author":"C Simonet","year":"2020","unstructured":"Simonet C, Tolosa E, Camara A, Valldeoriola F. Emergencies and critical issues in Parkinson\u2019s disease. Pract Neurol. 2020;20(1):15\u201325. https:\/\/doi.org\/10.1136\/practneurol-2018-002075.","journal-title":"Pract Neurol"},{"issue":"2","key":"1260_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1212\/01.wnl.0000129843.15756.a3","volume":"63","author":"L Marsh","year":"2004","unstructured":"Marsh L, Williams JR, Rocco M, Grill S, Munro C, Dawson TM. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology. 2004;63(2):293\u2013300. https:\/\/doi.org\/10.1212\/01.wnl.0000129843.15756.a3.","journal-title":"Neurology"},{"key":"1260_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.parkreldis.2019.10.018","volume":"68","author":"JB Wetmore","year":"2019","unstructured":"Wetmore JB, Li S, Yan H, Irfan M, Rashid N, Peng Y, et al. Increases in institutionalization, healthcare resource utilization, and mortality risk associated with Parkinson disease psychosis: Retrospective cohort study. Parkinsonism Relat Disord. 2019;68:95\u2013101. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.10.018.","journal-title":"Parkinsonism Relat Disord"},{"issue":"9916","key":"1260_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(13)62106-6.","journal-title":"Lancet"},{"issue":"5","key":"1260_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.9740\/mhc.2017.09.230","volume":"7","author":"KTB Touma","year":"2017","unstructured":"Touma KTB, Touma DC. Pimavanserin (Nuplazid) for the treatment of Parkinson disease psychosis: a review of the literature. Ment Health Clin. 2017;7(5):230\u20134. https:\/\/doi.org\/10.9740\/mhc.2017.09.230.","journal-title":"Ment Health Clin."},{"issue":"6","key":"1260_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2217\/nmt-2017-0028","volume":"7","author":"RB Schneider","year":"2017","unstructured":"Schneider RB, Iourinets J, Richard IH. Parkinson\u2019s disease psychosis: presentation, diagnosis and management. Neurodegener Dis Manag. 2017;7(6):365\u201376. https:\/\/doi.org\/10.2217\/nmt-2017-0028.","journal-title":"Neurodegener Dis Manag."},{"key":"1260_CR11","unstructured":"US Food and Drug Administration. US Food and Drug Administration. Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. 11 April 2005. http:\/\/web.archive.org\/web\/20160906021649\/http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm053171.htm. Accessed 7 Mar 2022."},{"issue":"1","key":"1260_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/archinternmed.2009.456","volume":"170","author":"ER Dorsey","year":"2010","unstructured":"Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010;170(1):96\u2013103. https:\/\/doi.org\/10.1001\/archinternmed.2009.456.","journal-title":"Arch Intern Med"},{"key":"1260_CR13","unstructured":"US Food and Drug Administration. US Food and Drug Administration. Information on conventional antipsychotics. 16 June 2008. https:\/\/wayback.archive-it.org\/7993\/20170722033234\/https:\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm107211.htm. Accessed 11 Mar 2022."},{"key":"1260_CR14","unstructured":"Pimavanserin Prescribing Information. Acadia Pharmaceuticals Inc. NUPLAZID (pimavanserin). April 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/207318lbl.pdf. Accessed 11 Mar 2022."},{"key":"1260_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jns.2017.01.012","volume":"374","author":"HA Hanagasi","year":"2017","unstructured":"Hanagasi HA, Tufekcioglu Z, Emre M. Dementia in Parkinson\u2019s disease. J Neurol Sci. 2017;374:26\u201331. https:\/\/doi.org\/10.1016\/j.jns.2017.01.012.","journal-title":"J Neurol Sci"},{"key":"1260_CR16","unstructured":"US Food and Drug Administration. FDA analysis finds no new or unexpected safety risks associated with Nuplazid (pimavanserin), a medication to treat the hallucinations and delusions of Parkinson\u2019s disease psychosis. 20 February 2018. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-analysis-finds-no-new-or-unexpected-safety-risks-associated-nuplazid-pimavanserin-medication. Accessed 18 Feb 2022."},{"key":"1260_CR17","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.21090876","author":"AD Mosholder","year":"2022","unstructured":"Mosholder AD, Ma Y, Akhtar S, Podskalny GD, Feng Y, Lyu H, et al. Mortality among Parkinson\u2019s disease patients treated with pimavanserin or atypical antipsychotics: an observational study in medicare beneficiaries. Am J Psychiatry. 2022. https:\/\/doi.org\/10.1176\/appi.ajp.21090876.","journal-title":"Am J Psychiatry"},{"issue":"13","key":"1260_CR18","doi-asserted-by":"publisher","first-page":"e1266","DOI":"10.1212\/WNL.0000000000012601","volume":"97","author":"YJ Hwang","year":"2021","unstructured":"Hwang YJ, Alexander GC, An H, Moore TJ, Mehta HB. Risk of hospitalization and death associated with pimavanserin use in older adults with Parkinson disease. Neurology. 2021;97(13):e1266\u201375. https:\/\/doi.org\/10.1212\/WNL.0000000000012601.","journal-title":"Neurology"},{"issue":"9","key":"1260_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161689","volume":"11","author":"L Kalilani","year":"2016","unstructured":"Kalilani L, Asgharnejad M, Palokangas T, Durgin T. Comparing the incidence of falls\/fractures in Parkinson\u2019s disease patients in the US population. PLoS ONE. 2016;11(9): e0161689. https:\/\/doi.org\/10.1371\/journal.pone.0161689.","journal-title":"PLoS ONE"},{"issue":"1","key":"1260_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/pds.3719","volume":"24","author":"KR Faurot","year":"2015","unstructured":"Faurot KR, Jonsson Funk M, Pate V, Brookhart MA, Patrick A, Hanson LC, et al. Using claims data to predict dependency in activities of daily living as a proxy for frailty. Pharmacoepidemiol Drug Saf. 2015;24(1):59\u201366. https:\/\/doi.org\/10.1002\/pds.3719.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"25","key":"1260_CR21","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107. https:\/\/doi.org\/10.1002\/sim.3697.","journal-title":"Stat Med"},{"key":"1260_CR22","unstructured":"Parsons L. Performing a 1:N case-control match on propensity score. Presented at the SUGI 29 Proceedings: SAS Users Group International Conference; 2004. Montreal, Canada."},{"issue":"6","key":"1260_CR23","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/sim.6004","volume":"33","author":"PC Austin","year":"2014","unstructured":"Austin PC. A comparison of 12 algorithms for matching on the propensity score. Stat Med. 2014;33(6):1057\u201369. https:\/\/doi.org\/10.1002\/sim.6004.","journal-title":"Stat Med"},{"issue":"2","key":"1260_CR24","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150\u201361. https:\/\/doi.org\/10.1002\/pst.433.","journal-title":"Pharm Stat"},{"key":"1260_CR25","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/acprof:oso\/9780195124408.001.0001","volume-title":"Multivariate methods in epidemiology","author":"TR Holford","year":"2002","unstructured":"Holford TR. Proportional hazards regression. In: Multivariate methods in epidemiology. New York: Oxford University Press; 2002. p. 239\u201340."},{"key":"1260_CR26","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/acprof:oso\/9780195152968.003.0015","volume-title":"Applied longitudinal data analysis: modeling change and event occurrence","author":"JD Singer","year":"2003","unstructured":"Singer JD, Willett JB. Extending the Cox regression model. In: Sps S, editor. Applied longitudinal data analysis: modeling change and event occurrence. New York: Oxford University Press, Inc.; 2003. p. 543\u201379."},{"key":"1260_CR27","first-page":"238","volume-title":"Modern epidemiology","author":"S Greenland","year":"2008","unstructured":"Greenland S, Rothman KJ. Introduction to categorical statistics. In: Rothman KJ, Greenland S, Lash T, editors. Modern epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 238\u201357.","edition":"3"},{"issue":"1","key":"1260_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/ADR-170042","volume":"2","author":"SJ Ralph","year":"2018","unstructured":"Ralph SJ, Espinet AJ. Increased all-cause mortality by antipsychotic drugs: updated review and meta-analysis in dementia and general mental health care. J Alzheimers Dis Rep. 2018;2(1):1\u201326. https:\/\/doi.org\/10.3233\/ADR-170042.","journal-title":"J Alzheimers Dis Rep."},{"issue":"8","key":"1260_CR29","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1177\/070674371506000805","volume":"60","author":"P Kurdyak","year":"2015","unstructured":"Kurdyak P, Lin E, Green D, Vigod S. Validation of a population-based algorithm to detect chronic psychotic illness. Can J Psychiatry. 2015;60(8):362\u20138. https:\/\/doi.org\/10.1177\/070674371506000805.","journal-title":"Can J Psychiatry"},{"issue":"1","key":"1260_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5334\/egems.281","volume":"7","author":"CC Stewart","year":"2019","unstructured":"Stewart CC, Lu CY, Yoon TK, Coleman KJ, Crawford PM, Lakoma MD, et al. Impact of ICD-10-CM transition on mental health diagnoses recording. EGEMS (Wash DC). 2019;7(1):14. https:\/\/doi.org\/10.5334\/egems.281.","journal-title":"EGEMS (Wash DC)."},{"key":"1260_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2021.07.018","author":"AG Hamedani","year":"2021","unstructured":"Hamedani AG, Weintraub D, Willis AW. Medicare claims data underestimate hallucinations in older adults with dementia. Am J Geriatr Psychiatry. 2021. https:\/\/doi.org\/10.1016\/j.jagp.2021.07.018.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"1260_CR32","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268\u201374. https:\/\/doi.org\/10.7326\/M16-2607.","journal-title":"Ann Intern Med"},{"key":"1260_CR33","unstructured":"EU PAS Register. EUPAS46331 Risk of Mortality Associated With Pimavanserin Use Compared With Other Atypical Antipsychotics in Patients With Parkinson\u2019s Disease\u2013Related Psychosis. 21 March 2022. https:\/\/www.encepp.eu\/encepp\/viewResource.htm?id=46332. Accessed 4 Apr 2022."},{"issue":"1","key":"1260_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000365590","volume":"43","author":"DA Butt","year":"2014","unstructured":"Butt DA, Tu K, Young J, Green D, Wang M, Ivers N, et al. A validation study of administrative data algorithms to identify patients with Parkinsonism with prevalence and incidence trends. Neuroepidemiology. 2014;43(1):28\u201337. https:\/\/doi.org\/10.1159\/000365590.","journal-title":"Neuroepidemiology"},{"issue":"4","key":"1260_CR35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","volume":"2","author":"JL Lund","year":"2015","unstructured":"Lund JL, Richardson DB, Sturmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2(4):221\u20138. https:\/\/doi.org\/10.1007\/s40471-015-0053-5.","journal-title":"Curr Epidemiol Rep."},{"issue":"6","key":"1260_CR36","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jval.2013.05.008","volume":"16","author":"JJ Gagne","year":"2013","unstructured":"Gagne JJ, Bykov K, Willke RJ, Kahler KH, Subedi P, Schneeweiss S. Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research. Value Health. 2013;16(6):1054\u201362. https:\/\/doi.org\/10.1016\/j.jval.2013.05.008.","journal-title":"Value Health."},{"issue":"1","key":"1260_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40801-021-00284-1","volume":"9","author":"JB Layton","year":"2022","unstructured":"Layton JB, Forns J, Turner ME, Dempsey C, Bartsch JL, Anthony MS, et al. Falls and fractures in patients with Parkinson\u2019s disease-related psychosis treated with pimavanserin vs atypical antipsychotics: a cohort study. Drugs Real World Outcomes. 2022;9(1):9\u201322. https:\/\/doi.org\/10.1007\/s40801-021-00284-1.","journal-title":"Drugs Real World Outcomes."},{"issue":"1","key":"1260_CR38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1192\/bjp.bp.112.122499","volume":"205","author":"T Gerhard","year":"2014","unstructured":"Gerhard T, Huybrechts K, Olfson M, Schneeweiss S, Bobo WV, Doraiswamy PM, et al. Comparative mortality risks of antipsychotic medications in community-dwelling older adults. Br J Psychiatry. 2014;205(1):44\u201351. https:\/\/doi.org\/10.1192\/bjp.bp.112.122499.","journal-title":"Br J Psychiatry"},{"issue":"9","key":"1260_CR39","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/aje\/kwr213","volume":"174","author":"KF Huybrechts","year":"2011","unstructured":"Huybrechts KF, Brookhart MA, Rothman KJ, Silliman RA, Gerhard T, Crystal S, et al. Comparison of different approaches to confounding adjustment in a study on the association of antipsychotic medication with mortality in older nursing home patients. Am J Epidemiol. 2011;174(9):1089\u201399.","journal-title":"Am J Epidemiol"},{"issue":"10 Supl 2","key":"1260_CR40","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1097\/MLR.0b013e318070c08e","volume":"45","author":"S Schneeweiss","year":"2007","unstructured":"Schneeweiss S, Patrick AR, St\u00fcrmer T, Brookhart MA, Avorn J, Maclure M, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007;45(10 Supl 2):S131\u201342. https:\/\/doi.org\/10.1097\/MLR.0b013e318070c08e.","journal-title":"Med Care"},{"issue":"1","key":"1260_CR41","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12883-021-02265-x","volume":"21","author":"TP Pham Nguyen","year":"2021","unstructured":"Pham Nguyen TP, Abraham DS, Thibault D, Weintraub D, Willis AW. Low continuation of antipsychotic therapy in Parkinson disease\u2014intolerance, ineffectiveness, or inertia? BMC Neurol. 2021;21(1):240. https:\/\/doi.org\/10.1186\/s12883-021-02265-x.","journal-title":"BMC Neurol"},{"issue":"4","key":"1260_CR42","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/ije\/dys223","volume":"42","author":"KJ Rothman","year":"2013","unstructured":"Rothman KJ, Gallacher JE, Hatch EE. Why representativeness should be avoided. Int J Epidemiol. 2013;42(4):1012\u20134. https:\/\/doi.org\/10.1093\/ije\/dys223.","journal-title":"Int J Epidemiol"},{"issue":"7","key":"1260_CR43","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1007\/s11606-013-2755-z","volume":"29","author":"KJ Rothman","year":"2014","unstructured":"Rothman KJ. Six persistent research misconceptions. J Gen Intern Med. 2014;29(7):1060\u20134. https:\/\/doi.org\/10.1007\/s11606-013-2755-z.","journal-title":"J Gen Intern Med"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01260-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-022-01260-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01260-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T15:44:23Z","timestamp":1674834263000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-022-01260-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1260"],"URL":"https:\/\/doi.org\/10.1007\/s40264-022-01260-6","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]},"assertion":[{"value":"22 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted by researchers at RTI Health Solutions, an independent nonprofit research organization. Funding for the research was received from Acadia Pharmaceuticals Inc., the manufacturer of pimavanserin. The contract between RTI Health Solutions and Acadia Pharmaceuticals Inc. includes independent publication rights.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MET and CD are employees of Acadia Pharmaceuticals Inc., the manufacturer of pimavanserin. JBL, JF, HED, LJM, and MSA are employees of RTI Health Solutions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The data that support the findings of this study are available from the US Centers for Medicare and Medicaid Services (CMS), but restrictions apply to the availability of these data, which were used under license for the current study and so are not publicly available. The authors are not authorized to release data based on CMS privacy policies. Data are however available with permission from CMS () upon the establishment of a data use agreement.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"This analysis was determined to be exempt from institutional review board (IRB) review by the RTI International (RTI) IRB on December 14, 2020 (RTI IRB Study ID 00021361). The US CMS Privacy Board approved the use of Medicare Research Identifiable Files for this study under a data use agreement with RTI Health Solutions.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The RTI IRB determined that individual-level consent was not required for this analysis of secondary, deidentified data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"JBL and JF contributed to the conceptualization, methodology, visualization, and writing of the original draft. HED contributed to the resources, project administration, and writing for the review and editing drafts of the manuscript. LJM contributed to the methodology, software, formal analysis, data curation, and writing for the review and editing drafts of the manuscript. MET contributed to the conceptualization, funding acquisition, and writing for the review and editing drafts. CD contributed to the conceptualization and writing of the review and editing drafts. MSA contributed to the conceptualization, supervision, funding acquisition, and writing of the review and editing drafts. All authors have read and approved the final version of the manuscript and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}